10x Genomics, Inc. (NASDAQ:TXG) CEO Serge Saxonov Sells 2,676 Shares

10x Genomics, Inc. (NASDAQ:TXGGet Rating) CEO Serge Saxonov sold 2,676 shares of 10x Genomics stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $34.07, for a total value of $91,171.32. Following the completion of the transaction, the chief executive officer now owns 974,926 shares of the company’s stock, valued at approximately $33,215,728.82. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

10x Genomics Price Performance

TXG traded up $1.28 during trading hours on Thursday, reaching $36.44. The company’s stock had a trading volume of 711,354 shares, compared to its average volume of 1,642,890. The business’s 50-day moving average is $30.63 and its 200-day moving average is $38.09. 10x Genomics, Inc. has a fifty-two week low of $23.81 and a fifty-two week high of $157.74. The stock has a market cap of $4.17 billion, a PE ratio of -24.62 and a beta of 1.58.

10x Genomics (NASDAQ:TXGGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. 10x Genomics had a negative return on equity of 21.01% and a negative net margin of 33.20%. The company had revenue of $131.10 million for the quarter, compared to analysts’ expectations of $129.13 million. During the same period in the prior year, the firm earned ($0.15) earnings per share. The firm’s revenue was up 4.6% compared to the same quarter last year. Analysts expect that 10x Genomics, Inc. will post -1.61 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Morgan Stanley cut their price objective on 10x Genomics from $70.00 to $64.00 and set an “overweight” rating for the company in a research note on Friday, November 4th. Cowen boosted their price objective on 10x Genomics from $50.00 to $55.00 in a research note on Tuesday, August 9th. JPMorgan Chase & Co. cut their price objective on 10x Genomics from $65.00 to $55.00 in a research note on Thursday, November 3rd. Cowen boosted their price objective on 10x Genomics to $55.00 in a research note on Monday, August 15th. Finally, Citigroup dropped their price target on 10x Genomics from $100.00 to $65.00 in a research report on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $51.13.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TXG. Wipfli Financial Advisors LLC acquired a new stake in shares of 10x Genomics in the third quarter valued at $26,000. First Horizon Advisors Inc. raised its stake in shares of 10x Genomics by 14,780.0% in the second quarter. First Horizon Advisors Inc. now owns 744 shares of the company’s stock valued at $33,000 after acquiring an additional 739 shares in the last quarter. Atlas Capital Advisors LLC raised its stake in shares of 10x Genomics by 45.5% in the third quarter. Atlas Capital Advisors LLC now owns 1,360 shares of the company’s stock valued at $39,000 after acquiring an additional 425 shares in the last quarter. Standard Family Office LLC acquired a new stake in shares of 10x Genomics in the first quarter valued at $59,000. Finally, Rockefeller Capital Management L.P. raised its stake in shares of 10x Genomics by 95.2% in the third quarter. Rockefeller Capital Management L.P. now owns 2,875 shares of the company’s stock valued at $81,000 after acquiring an additional 1,402 shares in the last quarter. 74.10% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Further Reading

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.